Antioxidative and Cardioprotective Effects of Minocycline in Ischemia/reperfusion Injury in Experimental Model of Hypertension

Overview

Journal Mol Cell Biochem

Publisher Springer

Specialty Biochemistry

Date 2024 Aug 26

PMID 39187740

Authors

Tamara Rudic

Aleksandra Stojanovic

Nikola Sobot

Jovana Novakovic

Sergey Bolevich

Stefani Bolevich

Vladimir Fisenko

Irina Nikolaevna Krylova

Marina Nikolic

Vladimir Jakovljevic

Ivan Srejovic

Affiliations

Soon will be listed here.

Abstract

Cardiovascular diseases remains leading cause of death and disabilities. Coronary artery occlusion and consequent ischemia leads to acute myocardial infarction, but restoration of blood flow, paradoxically, provokes further myocardial damage known as reperfusion injury. Minocycline is possessing anti-inflammatory and anti-apoptotic activity, immune-modulating and antioxidative properties besides its primary antibacterial effect. Recently it gained significant interest in preventing cardiac damage especially due to myocardial ischemia/reperfusion injury (MI/RI). The aim of this study was to assess the protective ability of pre-treatment and post-treatment of isolated hearts from healthy and spontaneously hypertensive rats with minocycline, on functional recovery and redox status after MI/RI using Langendorff technique. Using sensor in the left ventricle, the cardiodynamic parameters were recorded and in the samples of the coronary venous effluent oxidative stress biomarkers were analyzed. Minocycline was injected directly into the coronary vessels, in pre-treatment 5 min before global ischemia, and in post-treatment during the first 5 min of reperfusion. Changes in redox balance induced by minocycline were more prominent in post-treatment fashion of application. Cardioprotective effects of minocycline due to MI/RI are even more significant in hypertensive hearts. Minocycline showed significant cardioprotective effects, which was more pronounced in hypertensive compared to healthy hearts. Reduction of pro-oxidative biomarkers was more prominent in hypertensive hearts compared to the normotensive, especially if it is applied in the form of post-treatment. Minocycline could be important tool in reduction of heart damage induced by MI/RI due to its antioxidative potential, if these results are confirmed by clinical study.

References

Malakar A, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S . A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol. 2019; 234(10):16812-16823. DOI: 10.1002/jcp.28350. View

Xiang M, Lu Y, Xin L, Gao J, Shang C, Jiang Z . Role of Oxidative Stress in Reperfusion following Myocardial Ischemia and Its Treatments. Oxid Med Cell Longev. 2021; 2021:6614009. PMC: 8149218. DOI: 10.1155/2021/6614009. View

Daiber A, Andreadou I, Oelze M, Davidson S, Hausenloy D . Discovery of new therapeutic redox targets for cardioprotection against ischemia/reperfusion injury and heart failure. Free Radic Biol Med. 2020; 163:325-343. DOI: 10.1016/j.freeradbiomed.2020.12.026. View

Hausenloy D, Barrabes J, Botker H, Davidson S, Di Lisa F, Downey J . Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery. Basic Res Cardiol. 2016; 111(6):70. PMC: 5073120. DOI: 10.1007/s00395-016-0588-8. View

Ong S, Hernandez-Resendiz S, Crespo-Avilan G, Mukhametshina R, Kwek X, Cabrera-Fuentes H . Inflammation following acute myocardial infarction: Multiple players, dynamic roles, and novel therapeutic opportunities. Pharmacol Ther. 2018; 186:73-87. PMC: 5981007. DOI: 10.1016/j.pharmthera.2018.01.001. View

Hernandez-Resendiz S, Chinda K, Ong S, Cabrera-Fuentes H, Zazueta C, Hausenloy D . The Role of Redox Dysregulation in the Inflammatory Response to Acute Myocardial Ischaemia-reperfusion Injury - Adding Fuel to the Fire. Curr Med Chem. 2017; 25(11):1275-1293. DOI: 10.2174/0929867324666170329100619. View

Pedrinelli R, Ballo P, Fiorentini C, Denti S, Galderisi M, Ganau A . Hypertension and acute myocardial infarction: an overview. J Cardiovasc Med (Hagerstown). 2012; 13(3):194-202. DOI: 10.2459/JCM.0b013e3283511ee2. View

Qi S, Zhan Y, Chen Y, Xu T . Effect of Antecedent Hypertension on Mortality After Acute Coronary Syndromes in the Coronary Intervention Era: A Meta-analysis. Heart Lung Circ. 2023; 32(10):1189-1197. DOI: 10.1016/j.hlc.2023.08.007. View

Sun X, Feng Y, Gong C, Bao X, Wei Z, Chang L . Hypertension-Driven Regulatory T-Cell Perturbations Accelerate Myocardial Ischemia-Reperfusion Injury. Hypertension. 2023; 80(10):2046-2058. DOI: 10.1161/HYPERTENSIONAHA.123.20481. View

10.

Feng D, Yang C, Geurts A, Kurth T, Liang M, Lazar J . Increased expression of NAD(P)H oxidase subunit p67(phox) in the renal medulla contributes to excess oxidative stress and salt-sensitive hypertension. Cell Metab. 2012; 15(2):201-8. PMC: 3280886. DOI: 10.1016/j.cmet.2012.01.003. View

11.

Caricati-Neto A, Errante P, Menezes-Rodrigues F . Recent Advances in Pharmacological and Non-Pharmacological Strategies of Cardioprotection. Int J Mol Sci. 2019; 20(16). PMC: 6720817. DOI: 10.3390/ijms20164002. View

12.

Roth S, Torregroza C, Feige K, Preckel B, Hollmann M, Weber N . Pharmacological Conditioning of the Heart: An Update on Experimental Developments and Clinical Implications. Int J Mol Sci. 2021; 22(5). PMC: 7959135. DOI: 10.3390/ijms22052519. View

13.

Jeremic N, Petkovic A, Srejovic I, Zivkovic V, Djuric D, Jakovljevic V . Effects of ischemia and omeprazole preconditioning on functional recovery of isolated rat heart. Rev Bras Cir Cardiovasc. 2015; 30(2):266-75. PMC: 4462974. DOI: 10.5935/1678-9741.20150020. View

14.

Garrido-Mesa N, Zarzuelo A, Galvez J . Minocycline: far beyond an antibiotic. Br J Pharmacol. 2013; 169(2):337-52. PMC: 3651660. DOI: 10.1111/bph.12139. View

15.

Brenes-Salazar J . Minocycline: a bacteriostatic antibiotic with pleiotropic cardioprotective effects. Can J Physiol Pharmacol. 2015; 93(10):863-6. DOI: 10.1139/cjpp-2014-0493. View

16.

Sobot N, Sobot T, Jeremic J, Bolevich S, Bolevich S, Mitrovic S . Minocycline as heart conditioning agent in experimental type 2 diabetes mellitus - an antibacterial drug in heart protection. Naunyn Schmiedebergs Arch Pharmacol. 2022; 395(4):429-444. DOI: 10.1007/s00210-021-02179-y. View

17.

Romero-Perez D, Fricovsky E, Yamasaki K, Griffin M, Barraza-Hidalgo M, Dillmann W . Cardiac uptake of minocycline and mechanisms for in vivo cardioprotection. J Am Coll Cardiol. 2008; 52(13):1086-94. PMC: 2572824. DOI: 10.1016/j.jacc.2008.06.028. View

18.

Salameh A, Halling M, Seidel T, Dhein S . Effects of minocycline on parameters of cardiovascular recovery after cardioplegic arrest in a rabbit Langendorff heart model. Clin Exp Pharmacol Physiol. 2015; 42(12):1258-65. DOI: 10.1111/1440-1681.12485. View

19.

Yoshida T, Das N, Carpenter A, Izadpanah R, Kumar S, Gautam S . Minocycline reverses IL-17A/TRAF3IP2-mediated p38 MAPK/NF-κB/iNOS/NO-dependent cardiomyocyte contractile depression and death. Cell Signal. 2020; 73:109690. PMC: 7391223. DOI: 10.1016/j.cellsig.2020.109690. View

20.

Rankovic M, Jakovljevic V, Bradic J, Jakovljevic B, Zivkovic V, Srejovic I . Effects of High Intensity Interval vs. Endurance Training on Cardiac Parameters in Ischemia/Reperfusion of Male Rats: Focus on Oxidative Stress. Front Physiol. 2021; 12:534127. PMC: 7937794. DOI: 10.3389/fphys.2021.534127. View